Funding for this research was provided by:
National Natural Science Foundation of China (81788101, 81922028)
Youth Innovation Promotion Association of the Chinese Academy of Sciences (2019442)
the China National Center for Biotechnology Development 182 (2020YFC0843800)
Text and Data Mining valid from 2020-04-14
Received: 16 March 2020
Accepted: 9 April 2020
First Online: 14 April 2020
Ethics approval and consent to participate
: All patients had signed informed consent before using tocilizumab and agreed to publish case series. Ethical approval (No. 2020-XG (H)-005) was conducted in accordance with the international conference on Hamonisation Guidelines for good clinical practice and the Declaration of Helsinki and institutional ethics guidelines and obtained from the Ethics Committee from The First Affiliated Hospital of University of Science & Technology of China for emerging infectious diseases.
: Not applicable.
: The authors declare no competing interests.